Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07121244 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study of 68Ga-R11228 and 177Lu-R11228 in Breast Cancer
A Phase 1 study of Locoregionally Recurrent Hormone-receptor Positive Breast Cancer and Metastatic Hormone Receptor Positive Breast Cancer, sponsored by Radionetics Oncology.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 62
- Enrollment target
- 7
- Study locations
NCT07121244: Recruiting Phase 1 study of Locoregionally Recurrent Hormone-receptor Positive Breast Cancer and Metastatic Hormone Receptor Positive Breast Cancer, sponsored by Radionetics Oncology.
NCT07121244 is a Phase 1 study of Locoregionally Recurrent Hormone-receptor Positive Breast Cancer and Metastatic Hormone Receptor Positive Breast Cancer that is actively recruiting participants, run by Radionetics Oncology. The registered enrollment target is 62 participants, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target. The trial reports 7 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07121244, a Phase 1 study of Locoregionally Recurrent Hormone-receptor Positive Breast Cancer and Metastatic Hormone Receptor Positive Breast Cancer, is actively recruiting participants, sponsored by Radionetics Oncology.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 62 participants
- Enrollment target
- 7
- Study locations
Study Summary
A phase 1 study of 68Ga-R11228 and 177Lu-R11228 in breast cancer.
Primary Outcome
Number of participants with adverse events as assessed by NCI-CTCAE v5.0, including grade
Conditions Studied
Interventions
- DRUG 68Ga-R11228
- DRUG 177Lu-R11228
Study Locations (7)
Indiana
- Indiana University Melvin and Bren Simon Cancer Center - Indianapolis
Maryland
- United Theranostics - Glen Burnie
New Jersey
- United Theranostics Princeton - Princeton
Ohio
- University Hospital Seidman Cancer Center - Cleveland
Texas
- MD Anderson Cancer Center - Houston
Utah
- University of Utah - Huntsman Cancer Institute - Salt Lake City
Other
- Melbourne Theranostic Innovation Centre (MTIC) - Melbourne
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2025-10-01 |
| Est. Completion | 2033-06-01 |
| Phase | Phase 1 |
What NCT07121244 shows while recruiting
NCT07121244 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 62 participants, a relatively small participant target, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target.
The record links to 2 conditions, with Locoregionally Recurrent Hormone-receptor Positive Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which 68Ga-R11228 is the first listed.
NCT07121244 lists 7 locations in 7 states (Indiana, Maryland, New Jersey).
Frequently Asked Questions
What is clinical trial NCT07121244 about?
NCT07121244 is a clinical study titled "A Phase 1 Study of 68Ga-R11228 and 177Lu-R11228 in Breast Cancer". A phase 1 study of 68Ga-R11228 and 177Lu-R11228 in breast cancer.
What is the current status of trial NCT07121244?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 62 participants. The study started on 2025-10-01. Estimated completion is 2033-06-01.
What conditions does trial NCT07121244 study?
This clinical trial studies the following conditions: Locoregionally Recurrent Hormone-receptor Positive Breast Cancer, Metastatic Hormone Receptor Positive Breast Cancer.
What interventions are being tested in trial NCT07121244?
The interventions under investigation include: 68Ga-R11228 (DRUG), 177Lu-R11228 (DRUG).
Who is sponsoring clinical trial NCT07121244?
This trial is sponsored by Radionetics Oncology, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07121244 being conducted?
This trial has 7 study locations across Indiana, Maryland, New Jersey, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Locoregionally Recurrent Hormone-receptor Positive Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07121244's enrollment target sits among peer trials
62 825th of 2000 higher than 1,173 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03231150 · 62 participants · NA
Plantar Fasciitis Randomized Clinical Control Trial
- NCT03458676 · 62 participants · NA
Radiologic Pathologic Correlation of Advanced MR Imaging to Guide the Biopsy of Cerebral Malignancies
- NCT03596086 · 62 participants · Phase 1
HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM
- NCT03603405 · 62 participants · Phase 1
HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI